8-K: Core Scientific to Merge with CoreWeave in All-Stock Deal

Core Scientific's Board unanimously recommends stockholders vote for the all-stock merger with CoreWeave, citing significant pro forma benefits and de-risked growth.

Summary

• Core Scientific stockholders are set to receive 0.1235 newly-issued shares of CoreWeave Class A common stock for each share of Core Scientific common stock held.
• The exchange ratio of 0.1235 reflects a ~71% premium to the 10-day Volume Weighted Average Price (VWAP) exchange ratio as of June 25, 2025, prior to media reports regarding a transaction.
• Core Scientific stockholders will collectively receive an 8.9% ownership stake in the combined leading AI platform.
• The proposed combination eliminates Core Scientific's standalone execution risk on timely delivery of leased data centers and projected future leasing, as well as its ~$7.3 billion financing need.
• The transaction was unanimously approved by the board of directors of both companies and is expected to close in Q4 2025, subject to Core Scientific stockholder approval.
• CoreWeave is Core Scientific's primary colocation customer, projected to account for ~95% of its colocation revenue and ~76% of its total projected revenue by 2026E.
• The majority of Core Scientific's current forward-looking value is based on existing CoreWeave contracts.

Sentiment

Score: 9

Explanation: The merger offers a substantial premium to Core Scientific shareholders, effectively de-risking the company's future by eliminating a massive capital expenditure requirement and associated financing challenges. It provides ownership in a rapidly growing AI infrastructure leader with strong strategic fit and significant synergy potential.

Positives

• The proposed transaction provides significant pro forma combination benefits, with closely linked companies de-risking integration and benefiting from combined operations.
• The merger eliminates Core Scientific's standalone execution risk related to timely delivery of leased data centers and future leasing, as well as its ~$7.3 billion financing need.
• Core Scientific stockholders will receive an attractive exchange ratio of 0.1235 shares of CoreWeave for each Core Scientific share, representing a ~71% premium to the 10-day VWAP as of June 25, 2025.
• Through extensive negotiations, Core Scientific obtained an approximately 34% increase in the exchange ratio from CoreWeave's initial offer.
• Core Scientific stockholders will gain an 8.9% ownership in a leading AI platform with strong momentum and potential for incremental price appreciation via multiple expansion.
• The transaction accelerates and de-risks the path to scale for both companies, with the majority of Core Scientific's asset base already reserved by CoreWeave.
• Verticalization creates a differentiated leading large-cap AI infrastructure player, strengthening the combined company's end-to-end AI technology stack.
• Estimated $500 million+ fully ramped, annual run rate cost savings are expected by the end of 2027E for the combined company, including lease overhead elimination.
• The combined entity is expected to have a more liquid pro forma trading security, potentially reducing volatility compared to individual standalone companies.
• The transaction strengthens CoreWeave's capital position by converting a cash contract to an equity position and accelerates growth.
• The combination expands CoreWeave's addressable market, positioning it to capture a greater share of the ~$400 billion AI infrastructure market by 2028E.
• The pro forma company will gain greater control over a critical power footprint of ~1.3GW+ and optionality for future power capacity.
• The transaction enables Core Scientific to augment CoreWeave's expertise in power, construction, and site management.
• CoreWeave has a current revenue backlog of over $55 billion, a 4x increase from 2024, reinforcing strong AI compute demand.

Negatives

• Core Scientific's standalone plan included significant execution risks, particularly regarding timely delivery of data centers and future leasing.
• The standalone plan projected ~$7.3 billion of total capital expenditures over the next eight years, with over 75% ($5.7 billion) required in the first four years, leading to negative unlevered free cash flow for the colocation pipeline until 2030E.
• Financing for the standalone plan would have required raising substantial debt capital, leading to a sizeable increase in leverage and potentially very expensive or unfeasible debt financing without contracted revenue.
• Core Scientific's standalone business profile was considered sub-scale with significant single customer risk (CoreWeave).
• The CapEx buildout for Core Scientific's colocation pipeline was projected to be significantly more expensive (approximately 8x higher per MW) than contracted CapEx, and much of it would require pre-funding without customer contracts.
• CoreWeave indicated it was unwilling to pursue a fixed value deal (with or without a collar) or include cash in its proposal, as such terms would not be acceptable to its Board.
• CoreWeave stated that its final offer was its 'best and final,' limiting further negotiation for Core Scientific.

Risks

• The completion of the proposed transaction on anticipated terms or at all, and the timing thereof, including obtaining regulatory approvals and Core Scientific stockholder approval.
• Anticipated tax treatment, unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, future prospects, business and management strategies, and other conditions to the completion of the proposed transaction, including the possibility that any of the anticipated benefits will not be realized or will not be realized within the expected time period.
• The ability of Core Scientific and CoreWeave to integrate their businesses successfully and to achieve anticipated synergies and value creation.
• Potential litigation relating to the proposed transaction that could be instituted against Core Scientific, CoreWeave, or their respective directors and officers.
• The risk that disruptions from the proposed transaction will harm Core Scientific's or CoreWeave's business, including current plans and operations, and that management's time and attention will be diverted on transaction-related issues.
• Potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed transaction.
• Rating agency actions and Core Scientific's and CoreWeave's ability to access shortand long-term debt markets on a timely and affordable basis.
• Legislative, regulatory, and economic developments and actions targeting public companies in the artificial intelligence, power, data center, and crypto mining industries, and changes in local, national, or international laws, regulations, and policies affecting Core Scientific and CoreWeave.
• Potential business uncertainty, including the outcome of commercial negotiations and changes to existing business relationships during the pendency of the proposed transaction.
• Certain restrictions during the pendency of the proposed transaction that may impact Core Scientific's ability to pursue certain business opportunities or strategic transactions or otherwise operate its business.
• Acts of terrorism or outbreak of war, hostilities, civil unrest, attacks against Core Scientific or CoreWeave, and other political or security disturbances.
• Dilution caused by CoreWeave's issuance of additional shares of its securities in connection with the proposed transaction.
• The possibility that the transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events.
• The impacts of pandemics or other public health crises, including the effects of government responses on people and economies.
• Global or regional changes in the supply and demand for power and other market or economic conditions that impact demand and pricing.
• Changes in technical or operating conditions, including unforeseen technical difficulties.
• Development delays at Core Scientific's and/or CoreWeave's data center sites, including any delays in the conversion of such sites from crypto mining facilities to high-performance computing sites.
• Core Scientific's ability to earn digital assets profitably and to attract customers for its high-density colocation capabilities.
• Core Scientific's ability to perform under its existing colocation agreements.
• Core Scientific's ability to maintain its competitive position in its existing operating segments.
• The impact of increases in total network hash rate.
• Core Scientific's ability to raise additional capital to continue its expansion efforts or other operations.
• Core Scientific's need for significant electric power and the limited availability of power resources.
• The potential failure in Core Scientific's critical systems, facilities, or services the company provides.
• The physical risks and regulatory changes relating to climate change.
• Potential significant changes to the method of validating blockchain transactions.
• Core Scientific's vulnerability to physical security breaches, which could disrupt operations.
• A potential slowdown in market and economic conditions, particularly those impacting high-density computing, the blockchain industry, and the blockchain hosting market.
• Price volatility of digital assets and bitcoin in particular.
• Potential changes in the interpretive positions of the SEC or its staff with respect to digital asset mining firms.
• The likelihood that U.S. federal and state legislatures and regulatory agencies will enact laws and regulations to regulate digital assets and digital asset intermediaries.
• Changing expectations with respect to ESG policies.
• The effectiveness of Core Scientific's compliance and risk management methods.
• The adequacy of Core Scientific's sources of recovery if the digital assets held by Core Scientific are lost, stolen, or destroyed due to third-party digital asset services.

Future Outlook

The combined company is strategically positioned to capture a greater share of the rapidly expanding AI infrastructure market, projected to reach approximately $400 billion by 2028. The transaction is expected to generate significant cost savings, strengthen CoreWeave's capital position by converting a cash contract to an equity position, and accelerate growth. CoreWeave projects substantial revenue and EBITDA growth, which is anticipated to justify potential multiple expansion. The merger significantly de-risks Core Scientific's ability to secure financing for data center buildout and eliminates its substantial standalone capital expenditure needs.

Management Comments

• The Core Scientific Board of Directors unanimously determined that the proposed transaction with CoreWeave represents the best available alternative for all Core Scientific stockholders and recommends all stockholders vote FOR the transaction.
• The proposed transaction provides significant pro forma combination benefits; the companies are closely linked which de-risks integration and benefits from combined operations.
• The proposed combination eliminates standalone execution risk on timely delivery of currently leased data centers and projected future leasing in Core Scientifics current business plan (the Standalone Plan), as well as its ~$7.3 billion financing need.
• The Board oversaw the negotiation of an attractive exchange ratio that provides meaningful upfront premium and upside opportunity to Core Scientific stockholders.
• The proposed transaction was the result of a thoughtful Board-led evaluation of strategic alternatives.
• CoreWeave indicated it was unwilling to pursue a fixed value deal (with or without a collar) or include cash in its proposal, as such terms would not be acceptable to its Board.
• We believe that our best-of-breed software and infrastructure solution makes us optimally suited to capture these bleeding-edge training workloads.
• We believe that the mix of hardware across generations will ensure that we are optimally situated to capture all workload types, both inference and training.
• CoreWeave indicated that the June 27th offer represented its best and final offer.
• CoreWeave has since reaffirmed publicly on October 7th that its bid is best and final.

Industry Context

The merger creates a vertically integrated AI infrastructure player, combining Core Scientific's extensive data center and power assets with CoreWeave's specialized GPU cloud and AI software services. This strategic move positions the combined entity to capitalize on the rapidly expanding AI infrastructure market, which is projected to reach approximately $400 billion by 2028. CoreWeave has recently secured significant deals with major industry players like OpenAI (up to $6.5 billion) and Meta ($14.2 billion), underscoring strong demand for its high-performance computing services and its leading position in the sector. The verticalization strategy aims to enhance control over the supply chain, optimize delivery timelines, and reduce costs, which are critical factors for success in this highly competitive and capital-intensive industry.

Comparison to Industry Standards

• CoreWeave currently trades at a significant discount to publicly traded comparable pureplay and diversified cloud companies, including Alphabet Inc., Amazon.com, Inc., International Business Machines Corporation, Microsoft Corporation, Nebius Group N.V., and Oracle Corporation, despite its meaningfully higher growth projections.
• The transaction's exchange ratio premium of 71% to the 10-day VWAP unaffected exchange ratio places it within the top decile of all-stock exchange ratio transactions since 2004.
• Core Scientific's standalone CapEx per MW for pipeline buildout (estimated ~8x higher than contracted CapEx) is in line with typical data center builds, highlighting the cost efficiency and unique funding arrangement provided by CoreWeave for existing contracts.

Corporate Governance

Legal Proceedings

• Potential litigation relating to the proposed transaction that could be instituted against Core Scientific, CoreWeave, or their respective directors and officers is identified as a risk factor.

Related Party Transactions

• CoreWeave is Core Scientific's main colocation customer, projected to represent ~95% of its colocation revenue and ~76% of its total projected revenue by 2026E.
• CoreWeave agreements constitute the majority of Core Scientific's standalone plan Discounted Cash Flow (DCF) value, including an additional ~$1 billion tied to a discretionary five-year contract extension.
• CoreWeave and Core Scientific share a unique CapEx funding arrangement for contracted colocation, where CoreWeave pays for the CapEx, which is not expected to pertain to pipeline capacity.

Stakeholder Impact

• **Shareholders (Core Scientific):** Will receive a significant premium and ownership in a larger, more diversified, and high-growth AI infrastructure company, mitigating substantial standalone risks and offering upside potential.
• **Shareholders (CoreWeave):** Will benefit from vertical integration, enhanced control over critical data center infrastructure, operational efficiencies, and an accelerated path to scale in the booming AI market.
• **Employees:** The transaction is expected to generate significant cost savings through streamlining business operations, which could lead to organizational changes, but also opportunities within a larger, growing combined entity.
• **Customers (CoreWeave):** Customers, including major players like OpenAI and Meta, will benefit from enhanced control over infrastructure, optimized delivery timelines, and expanded capacity for high-performance computing.
• **Creditors:** The combined company is expected to have greater financial flexibility and a reduced overall cost of capital by pursuing infrastructure financing strategies for committed capital expenditures.

Next Steps

• A Special Meeting of Core Scientific stockholders is scheduled for October 30, 2025, to consider and vote upon the proposal to adopt the Agreement and Plan of Merger.
• The transaction is expected to close in Q4 2025, subject to the affirmative vote of a majority of Core Scientific's outstanding common shares.
• Following the closing, the integration of Core Scientific and CoreWeave businesses will commence.
• The combined company aims to realize estimated $500 million+ annual run rate cost savings by the end of 2027E.

Key Dates

Recommendation

The merger offers Core Scientific shareholders a substantial premium and ownership in a leading, high-growth AI infrastructure company, effectively de-risking its future operations and eliminating significant capital expenditure burdens. The strategic rationale is compelling, with strong synergies, cost savings, and an expanded market opportunity. For CoreWeave, it secures critical infrastructure and enhances vertical integration. This transaction is highly favorable for Core Scientific shareholders and positions the combined entity for strong future performance in a booming industry.

Keywords

Core Scientific, CoreWeave, Merger, Acquisition, All-stock transaction, AI infrastructure, Data center, Colocation, Bitcoin mining, HPC, GPU cloud, SEC filing, 8-K, CORZ, CORZW, CORZZ